Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15951249 | 0.88 | ATR (0.43) | ATRLCKKMT2ALMNACYP17A1 | |
| SCHEMBL25271015 | 0.86 | ATR (0.45) | ATRLCKCYP17A1MAPKAPK2METAP1 | |
| SCHEMBL12133550 | 0.86 | LCK (0.46) | ATRLCKKMT2ALMNACYP17A1 | |
| SCHEMBL6870765 | 0.86 | ATR (0.44) | ATRLCKKMT2ALMNACYP17A1 | |
| SCHEMBL16533461 | 0.84 | ATR (0.43) | ATRLCKKMT2ALMNACYP17A1 | |
| SCHEMBL16264333 | 0.84 | ATR (0.46) | ATRLCKKMT2ACYP17A1MAPKAPK2 | |
| SCHEMBL3710643 | 0.82 | MAPKAPK2 (0.45) | ATRLCKKMT2ALMNACYP17A1 | |
| SCHEMBL19384200 | 0.82 | XPO1 (0.44) | ATRLCKKMT2ALMNACYP17A1 | |
| SCHEMBL12133539 | 0.82 | ATR (0.44) | ATRLCKKMT2ALMNACYP17A1 | |
| SCHEMBL31120609 | 0.81 | LCK (0.43) | ATRLCKKMT2ALMNACYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021444-B2 | Antiviral compounds | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
| WO-2015026792-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| EP-2170339-B1 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8461189-B2 | Pyridyl derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461189-B2 | Pyridyl derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100324092-A1 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
| US-20100324092-A1 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
| US-20090156825-A1 | Fluorescent compounds that bind to histone deacetylase | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
| US-20090156825-A1 | Fluorescent compounds that bind to histone deacetylase | MERCK SHARP & DOHME CORP. | 2009-06-18 | — | — | US | disclosed |
| WO-2009005638-A2 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | ATR 1930/4885LCK 3440/4885KMT2A 4241/4885 |
| US-20090156825-A1 | Fluorescent compounds that bind to histone deacetylase | HDAC1, HDAC3, HDAC11 | ATR 4396/4885LCK 3388/4885KMT2A 145/4885 |
| US-11021444-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | ATR 1930/4885LCK 3440/4885KMT2A 4241/4885 |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | ATR 1930/4885LCK 3440/4885KMT2A 4241/4885 |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | ATR 1930/4885LCK 3440/4885KMT2A 4241/4885 |
| US-20100324092-A1 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | BRDT, HDAC5, HDAC1 | ATR 449/4885LCK 441/4885KMT2A 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.